Kantarjian, Hagop

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Vannucchi, A. M., Kantarjian, H. M., Kiladjian, J.-J., Gotlib, J., Cervantes, F., Mesa, R. A., Sarlis, N. J., Peng, W., Sandor, V., Gopalakrishna, P., et al. (2015) · Haematologica

Myeloproliferative Neoplasms: Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 260

Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

Sekeres, M. A., Schoonen, W. M., Kantarjian, H., List, A., Fryzek, J., Paquette, R., & Maciejewski, J. P. (2008) · JNCI: Journal of the National Cancer Institute

Acute Myeloid Leukemia ResearchHematological disorders and diagnostics

Cited by 248

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Wang, W., Cortes, J. E., Tang, G., Khoury, J. D., Wang, S., Bueso-Ramos, C. E., DiGiuseppe, J. A., Chen, Z., Kantarjian, H. M., Medeiros, L. J., et al. (2016) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 198

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

Schimmer, A. D., O'Brien, S., Kantarjian, H., Brandwein, J., Cheson, B. D., Minden, M. D., Yee, K., Ravandi, F., Giles, F., Schuh, A., et al. (2008) · Clinical Cancer Research

Acute Myeloid Leukemia ResearchCell death mechanisms and regulation

Cited by 192

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., et al. (2023) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchPhagocytosis and Immune Regulation

Cited by 188

Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

Cortes, J. E., Goldberg, S. L., Feldman, E. J., Rizzeri, D. A., Hogge, D. E., Larson, M., Pigneux, A., Recher, C., Schiller, G., Warzocha, K., et al. (2015) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 175

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 161

Dasatinib

Kantarjian, H., Jabbour, E., Grimley, J., & Kirkpatrick, P. (2006) · Nature Reviews Drug Discovery

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 149

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Apperley, J. F., Milojkovic, D., Cross, N. C. P., Hjorth-Hansen, H., Hochhaus, A., Kantarjian, H., Lipton, J. H., Malhotra, H., Niederwieser, D., Radich, J., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 139

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia

Naqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., et al. (2020) · Cancer

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 135

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 133

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

Ravandi, F., Kantarjian, H., Faderl, S., Garcia-Manero, G., O’Brien, S., Koller, C., Pierce, S., Brandt, M., Kennedy, D., Cortes, J., et al. (2010) · Leukemia Research

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 125

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers

Cortes, J., Tamura, K., DeAngelo, D. J., de Bono, J., Lorente, D., Minden, M., Uy, G. L., Kantarjian, H., Chen, L. S., Gandhi, V., et al. (2018) · British Journal of Cancer

Acute Myeloid Leukemia ResearchCancer Mechanisms and Therapy

Cited by 120

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 120

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Boddu, P., Kantarjian, H. M., Garcia-Manero, G., Ravandi, F., Verstovsek, S., Jabbour, E., Borthakur, G., Konopleva, M., Bhalla, K. N., Daver, N., et al. (2017) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 112

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Tashakori, M., Kadia, T., Loghavi, S., Daver, N., Kanagal-Shamanna, R., Pierce, S., Sui, D., Wei, P., Khodakarami, F., Tang, Z., et al. (2022) · Blood

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 111

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options

Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 105

Molecular Remissions Induced by Liposomal-Encapsulated All-Trans Retinoic Acid in Newly Diagnosed Acute Promyelocytic Leukemia

Estey, E. H., Giles, F. J., Kantarjian, H., O’Brien, S., Cortes, J., Freireich, E. J., Lopez-Berestein, G., & Keating, M. (1999) · Blood

Retinoids in leukemia and cellular processesAcute Myeloid Leukemia Research

Cited by 105

Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome

Colla, S., Ong, D. S. T., Ogoti, Y., Marchesini, M., Mistry, N. A., Clise-Dwyer, K., Ang, S. A., Storti, P., Viale, A., Giuliani, N., et al. (2015) · Cancer Cell

Telomeres, Telomerase, and SenescenceAcute Myeloid Leukemia Research

Cited by 105

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer

Acute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors Research

Cited by 104

Impact of the variant allele frequency of ASXL1 , DNMT3A , JAK2 , TET2 , TP53 , and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

Sasaki, K., Kanagal‐Shamanna, R., Montalban‐Bravo, G., Assi, R., Jabbour, E., Ravandi, F., Kadia, T., Pierce, S., Takahashi, K., Nogueras Gonzalez, G., et al. (2020) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 101

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformation

Kanagal‐Shamanna, R., Jain, P., Patel, K. P., Routbort, M., Bueso‐Ramos, C., Alhalouli, T., Khoury, J. D., Luthra, R., Ferrajoli, A., Keating, M., et al. (2019) · Cancer

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 98

The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality

Wang, E., Farmakiotis, D., Yang, D., McCue, D. A., Kantarjian, H. M., Kontoyiannis, D. P., & Mathisen, M. S. (2015) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 82

Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment

Jabbour, E., Parikh, S. A., Kantarjian, H., & Cortes, J. (2011) · Hematology/Oncology Clinics of North America

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 68